Sally Pipes, President, CEO and Thomas W. Smith Fellow in Healthcare Policy at the Pacific Research Institute, discusses how “Most Favored Nation” pricing schemes, which seek to import foreign price controls on prescription drugs, would harm innovation, undermine intellectual property rights and threaten America’s pharmaceutical supremacy, a better way to address foreign freeloading, the success of the Bayh-Dole Act, and more.